Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Note 5 - Cash, Cash Equivalents and Investments (Tables)

Note 5 - Cash, Cash Equivalents and Investments (Tables)

12 Months Ended

Dec. 31, 2022

Notes Tables

Cash, Cash Equivalents and Investments [Table Text Block]

		Total				Quoted prices in active markets (Level 1)				Significant other observable inputs (Level 2)				Significant unobservable inputs (Level 3)
December 31, 2022
Money market funds, included in cash equivalents		$	17,618			$	17,618			$	—			$	—
Investments - US treasuries			3,573				3,573				—				—
Investments - Foreign treasuries			896				896				—				—
Investments - Asset-backed securities			499				—				499				—
Investments - Corporate bonds			15,566				—				15,566				—
Total		$	38,152			$	22,087			$	16,065			$	—

		Total				Quoted prices in active markets (Level 1)				Significant other observable inputs (Level 2)				Significant unobservable inputs (Level 3)
December 31, 2021
Money market funds, included in cash equivalents		$	56,885			$	56,885			$	—			$	—
Total		$	56,885			$	56,885			$	—			$	—

Debt Securities, Available-for-Sale [Table Text Block]

		*Contractual maturity*
		(in days)			*Amortized Cost*				*Unrealized gains*				*Unrealized losses*				*Fair Value*
Investments
US treasuries		47-110			$	3,575			$	—			$	(2	)		$	3,573
Foreign treasuries		74				899				—				(3	)			896
Asset-backed securities		15				500				—				(1	)			499
Corporate bonds		5-228				15,633				—				(67	)			15,566
Total					$	20,607			$	—			$	(73	)		$	20,534